Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant quadrivalent HPV vaccine in Chinese women aged 18 to 45 years
ChiCTR1900025470Phase 3Recruiting
- Sponsor
- Hunan Center for Disease Control and Prevention
- Start
- Jan 2018
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quadrivalent human papillomavirus vaccine in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by Hunan Center for Disease Control and Prevention. Primary endpoints: 12 months of continuous infection associated with HPV types 6, 11, 16, and 18 and Prevention of HPV 6/11/16/18 type-specific CIN2+ lesions. Started Jan 2018; status: recruiting.
02
Drugs
quadrivalent human papillomavirus vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900025470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025470.